Orchid Pharma Ltd (ORCHPHARMA)
₹988.60
Mkt cap
₹5,014 Cr
P/E ratio
185.00
P/B
3.89
Div yield
0.00%
ROE
2.12%
ROCE
2.64%
EPS (TTM)
₹5.34
Book value
₹254
52W range
482–1,101
Sector
Healthcare
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthLow
TechnicalsBullish
52-week range
−10.24% from high₹989
₹482+104.91% from low₹1,101
Current
₹988.60
Prev close
₹999.00
Day
−1.04%
Price performance
1D
−1.04%
1W
−5.54%
1M
+2.63%
3M
+74.40%
6M
+41.07%
1Y
+33.35%
YTD
+24.41%
Financials
FRevenue, profit & margin
P/E ratio
185.0×
ORCHPHARMA is 444% above the sector median of 34.0×
ORCHPHARMA185.0×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 210 | 183 | 199 | 221 | 217 | 244 | 223 | 217 | 237 | 173 | 194 | 207 | 238 | |
| Expenses | 170 | 161 | 175 | 185 | 188 | 212 | 192 | 191 | 209 | 159 | 195 | 206 | 211 | |
| Operating Profit | 40 | 22 | 23 | 35 | 29 | 32 | 30 | 26 | 28 | 14 | -1 | 2 | 27 | |
| OPM % | 19% | 12% | 12% | 16% | 13% | 13% | 14% | 12% | 12% | 8% | -1% | 1% | 11% | |
| Other Income | 34 | 2 | 8 | 8 | 13 | 8 | 8 | 8 | 4 | 11 | 11 | -2 | 8 | |
| Interest | 7 | 6 | 4 | 4 | 3 | 4 | 3 | 4 | 4 | 3 | 4 | 3 | 3 | |
| Depreciation | 7 | 8 | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | |
| Profit before tax | 59 | 11 | 20 | 30 | 30 | 28 | 26 | 22 | 19 | 14 | -3 | -12 | 23 | |
| Tax % | 0% | 0% | 0% | 0% | -10% | -1% | 0% | 0% | -0% | 0% | 0% | 0% | 0% | |
| Net Profit | 59 | 9 | 20 | 29 | 33 | 29 | 27 | 21 | 22 | 15 | -6 | -13 | 24 | |
| EPS in Rs | 14.49 | 1.85 | 3.90 | 5.80 | 6.50 | 5.79 | 5.37 | 4.10 | 4.39 | 2.94 | -1.13 | -2.49 | 4.69 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202669.84%Promoter
Promoters69.84%
FIIs0.80%0.07
DIIs20.75%0.51
Public8.62%0.42
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Orchid Pharma | ₹988.60 | 184.89 | 5,014 | 0.00% | 24 | +4.26% | 238 | +0.05% | 2.64% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2013nseFinancial Year 2013bseFinancial Year 2012bseFinancial Year 2012nse
Concall transcripts45
TranscriptJun 2026PPTJun 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptJun 2025PPTJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024RECMay 2024TranscriptFeb 2024PPTFeb 2024RECFeb 2024TranscriptNov 2023
Credit ratings6
Announcements5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 11 Jul - Confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.Corporate Action For Fixation Of Record Date 10 JulAnnouncement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association 10 Jul - Scheme amalgamating Dhanuka Laboratories effective July 10, 2026; record date July 23, 2026; 161:5 share swap.Board Meeting Outcome for Intimation Under Regulations 30 Of SEBI (LODR) Regulations, 2015 As Amended ("SEBI Listing Regulations"). 10 Jul - Scheme with Dhanuka Laboratories effective July 10, 2026; record date July 23, 2026; 161:5 exchange ratio.Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited ('Amalgamating Company') With Orchid Pharma Limited ('Amalgamated Company/Company') And Their Respective Shareholders
And Creditors ('The Scheme') Under Regulation 30 Of SEBI (LODR) Regulations, 2015 '(SEBI Listing Regulations)', As Amended. 10 Jul - Orchid Pharma-Dhanuka Laboratories amalgamation became effective on July 10, 2026; Dhanuka dissolved.